Rhythm PHARMACEUTICALS, Inc. (RYTM) intrinsic value & 10-year financials
Rhythm PHARMACEUTICALS, Inc. (RYTM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 178.5% a year to $189.8M, with an average return on invested capital of -109.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $86.17
- Market cap
- $5.6B
- Revenue (FY2025)
- $189.8M
- Revenue growth (10-yr CAGR)
- 178.5%
- ROIC (10-yr avg)
- -109.4%
- Free cash flow (FY2025)
- -$116.6M
RYTM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $189.8M | -$196.5M | -$3.11 | -$116.6M | -101.2% | -158.3% |
| FY2024 | $130.1M | -$260.6M | -$4.34 | — | -204.0% | -202.2% |
| FY2023 | $77.4M | -$184.7M | -$3.20 | -$136.2M | -238.1% | -104.1% |
| FY2022 | $23.6M | -$181.1M | -$3.47 | -$173.7M | -757.9% | -98.8% |
| FY2021 | $3.2M | -$69.6M | -$1.40 | -$146.4M | -5391.9% | -46.9% |
| FY2020 | $0 | -$134.0M | -$3.04 | -$122.2M | — | -92.4% |
| FY2019 | $0 | -$140.7M | -$3.86 | -$126.1M | — | -63.4% |
| FY2018 | $0 | -$74.1M | — | -$62.8M | — | — |
| FY2017 | $0 | -$33.7M | — | -$29.6M | — | — |
| FY2016 | $0 | -$25.9M | — | -$24.3M | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
RHYTHM PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
RHYTHM PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just -58.5% ROIC.
RHYTHM PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, RHYTHM PHARMACEUTICALS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-103.30 per share.